Author:
Hens Bart,Talattof Arjang,Paixão Paulo,Bermejo Marival,Tsume Yasuhiro,Löbenberg Raimar,Amidon Gordon L.
Publisher
Springer Science and Business Media LLC
Reference76 articles.
1. Food and Drug Administration. Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system guidance for industry [Internet]. 2015. Available from:
http://www.fda.gov/downloads/Drugs/Guidances/ucm070246.pdf
. Accessed 17 Jan 2017.
2. Food and Drug Administration. Guidance for industry bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA [Internet]. 2013. Available from:
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM377465.pdf
. Accessed 20 Jan 2017.
3. Yu LX, Amidon GL, Polli JE, Zhao H, Mehta MU, Conner DP, et al. Biopharmaceutics classification system: the scientific basis for biowaiver extensions. Pharm Res. 2002;19(7):921–5.
4. Amidon GL, Lennernäs H, Shah VP, Crison JRA. Theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12(3):413–20.
5. Williams HD, Trevaskis NL, Charman SA, Shanker RM, Charman WN, Pouton CW, et al. Strategies to address low drug solubility in discovery and development. Pharmacol Rev. 2013;65(1):315–499.
Cited by
20 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献